Cases & Deals

  • Home
  • Practices
  • NeuExcell collaborates on development gene therapies for treatment of neurodegenerative diseases and neural injuries

Share

NeuExcell collaborates on development gene therapies for treatment of neurodegenerative diseases and neural injuries

August 2025

Client(s) NeuExcell Therapeutics Group

Jones Day is advising NeuExcell Therapeutics Group, a clinical-stage biotechnology company, on IP licensing strategies to support collaborations and partnerships for the clinical and commercial advancement of next-generation gene therapies for the treatment of neurodegenerative diseases and neural injuries by leveraging its proprietary in situ neural regeneration platform.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.